Transfusion hemosiderosis developed in aplastic anemia patients was treated with Desferrioxamine. Clinical studies were designed to evaluate the different ways of administration to obtain the maximal excretion of iron into urine.
Three patients had received 23,000, 10,000 and 30,000 ml of blood transfusion, respectively, before Desferrioxamine was initiated. All patients showed high serum iron levels with low unsaturated iron binding capacity. After the administration of Desferrioxamine, there was a significant increase of urinary iron excretion in all patients. In each individual, Desferrioxamine was given in various ways on different occasions and the following results were obtained;
1) Total iron excretion was higher with divided administration than with a single dosage.
2) There was no significant difference in iron excretion per day between daily and every other day administration. This suggests that daily administration could expedite excretion of iron to a greater extent than does a dose given every other day.
3) No significant iron excretion was observed in initial 24 hours after the administration of the drug, when it was given every other day.
4) There was no significant difference in urinary iron excretion between intramuscular and intravenous administrations.
5) No side effects were noted even after long-term treatment with this iron-chelating agent.
View full abstract